Immutep Ltd ADR (IMMP)

Fri, 15 May 2026 12:08:00 -0400 - 1 day ago

IMMP CLASS ACTION ALERT: Johnson Fistel Encourages Immutep Limited Shareholders to Submit Their Information Before July 6, 2026 Lead Plaintiff Deadline

Fri, 15 May 2026 10:24:00 -0400 - 1 day ago

IMMP Investors Have Opportunity to Lead Immutep Limited Securities Fraud Lawsuit with the Schall Law Firm

Fri, 15 May 2026 09:00:00 -0400 - 1 day ago

IMMP Shareholder Alert: Immutep Limited Securities Class Action Lawsuit - Investors With Losses May Contact The Gross Law Firm

Thu, 14 May 2026 22:07:00 -0400 - 1 day ago

ROSEN, A LEADING AND RANKED FIRM, Encourages Immutep Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action - IMMP

Thu, 14 May 2026 20:02:00 -0400 - 1 day ago

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Immutep Limited of Class Action Lawsuit and Upcoming Deadlines - IMMP

Thu, 14 May 2026 17:37:00 -0400 - 1 day ago

IMMP Class Action Notice: Robbins LLP Reminds Investors of the Lead Plaintiff Deadline in the Immutep Limited Class Action Lawsuit

Thu, 14 May 2026 12:00:00 -0400 - 2 days ago

Bronstein, Gewirtz & Grossman LLC Urges Immutep Limited Investors to Act: Class Action Filed Alleging Investor Harm

Thu, 14 May 2026 10:55:00 -0400 - 2 days ago

IMMP CLASS ACTION ALERT: Johnson Fistel Encourages Immutep Limited Shareholders to Submit Their Information Before July 6, 2026 Lead Plaintiff Deadline

Thu, 14 May 2026 10:19:00 -0400 - 2 days ago

IMMP INVESTOR NOTICE: Faruqi & Faruqi, LLP Reminds Immutep (IMMP) Investors of Securities Class Action Deadline on July 6, 2026

Thu, 14 May 2026 09:14:00 -0400 - 2 days ago

IMMUTEP LIMITED INVESTORS WITH LOSSES HAVE UNTIL JULY 6, 2026 TO JOIN SECURITIES CLASS ACTION – Bernstein Liebhard LLP Announces Deadline

Wed, 13 May 2026 13:13:00 -0400 - 3 days ago

ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Immutep Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action - IMMP

Wed, 13 May 2026 13:06:00 -0400 - 3 days ago

IMMP CLASS ACTION NOTICE: Faruqi & Faruqi, LLP Reminds Immutep (IMMP) Investors of Securities Class Action Deadline on July 6, 2026

Wed, 13 May 2026 12:00:00 -0400 - 3 days ago

Bronstein, Gewirtz & Grossman LLC Urges Immutep Limited Investors to Act: Class Action Filed Alleging Investor Harm

Wed, 13 May 2026 09:00:00 -0400 - 3 days ago

IMMP DEADLINE: Levi & Korsinsky Reminds Immutep Limited Investors of Upcoming Securities Class Action Deadline

Tue, 12 May 2026 18:56:00 -0400 - 3 days ago

ROSEN, A LEADING LAW FIRM, Encourages Immutep Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action - IMMP

Tue, 12 May 2026 16:55:00 -0400 - 3 days ago

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Immutep Limited of Class Action Lawsuit and Upcoming Deadlines – IMMP

Tue, 12 May 2026 10:42:00 -0400 - 4 days ago

IMMP Investors Have Opportunity to Lead Immutep Limited Securities Fraud Lawsuit with the Schall Law Firm

Tue, 12 May 2026 10:33:00 -0400 - 4 days ago

SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Immutep Limited (IMMP)

Tue, 12 May 2026 09:33:00 -0400 - 4 days ago

IMMP INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Immutep (IMMP) Investors of Securities Class Action Deadline on July 6, 2026

Tue, 12 May 2026 09:00:00 -0400 - 4 days ago

IMMP Shareholder Alert: Immutep Limited Securities Class Action Lawsuit - Investors With Losses May Contact The Gross Law Firm

Mon, 11 May 2026 18:51:00 -0400 - 4 days ago

ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Immutep Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action - IMMP

Mon, 11 May 2026 16:00:00 -0400 - 5 days ago

IMMP Shareholder Alert: Immutep Limited Securities Class Action Lawsuit - Investors With Losses May Contact Levi & Korsinsky

Mon, 11 May 2026 15:19:00 -0400 - 5 days ago

INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of Immutep Limited (IMMP) Investors – Holzer & Holzer, LLC Encourages Investors with Losses to Contact the Firm

Mon, 11 May 2026 12:00:00 -0400 - 5 days ago

Bronstein, Gewirtz & Grossman LLC Urges Immutep Limited Investors to Act: Class Action Filed Alleging Investor Harm

Sun, 10 May 2026 12:35:00 -0400 - 6 days ago

ROSEN, A TOP RANKED LAW FIRM, Encourages Immutep Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action - IMMP

Sun, 10 May 2026 09:00:00 -0400 - 6 days ago

Rosen Law Firm Encourages Immutep Ltd. Investors to Inquire About Securities Class Action Investigation - IMMP

Sat, 09 May 2026 06:18:00 -0400 - 7 days ago

IMMP INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Immutep (IMMP) Investors of Securities Class Action Deadline on July 6, 2026

Fri, 08 May 2026 17:31:00 -0400 - 7 days ago

IMMP Class Action Reminder - Robbins LLP Reminds Investors of the Lead Plaintiff Deadline in the Immutep Limited Class Action Lawsuit

Fri, 08 May 2026 16:01:00 -0400 - 8 days ago

IMMUTEP ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Immutep Ltd.

2026-05-08T16:50:59.000Z - 8 days ago

Largest borrow rate increases among liquid names

BITU CNQ EWG LAR MRLN QID RCAT

Fri, 08 May 2026 09:00:00 -0400 - 8 days ago

IMMP Shareholder Alert: Immutep Limited Securities Class Action Lawsuit - Investors Should Contact The Gross Law Firm

Thu, 07 May 2026 17:28:00 -0400 - 8 days ago

IMMP Investors Have Opportunity to Lead Immutep Limited Securities Fraud Lawsuit with the Schall Law Firm

Thu, 07 May 2026 16:04:00 -0400 - 9 days ago

ROSEN, A LEADING LAW FIRM, Encourages Immutep Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action - IMMP

Thu, 07 May 2026 16:04:00 -0400 - 9 days ago

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Immutep Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action - IMMP

Thu, 07 May 2026 12:00:00 -0400 - 9 days ago

Bronstein, Gewirtz & Grossman LLC Urges Immutep Limited Investors to Act: Class Action Filed Alleging Investor Harm

Thu, 07 May 2026 11:22:00 -0400 - 9 days ago

IMMP CLASS ACTION NOTICE: Faruqi & Faruqi, LLP Reminds Immutep (IMMP) Investors of Securities Class Action Deadline on July 6, 2026

Thu, 07 May 2026 10:00:00 -0400 - 9 days ago

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Immutep Limited of Class Action Lawsuit and Upcoming Deadlines - IMMP

Thu, 07 May 2026 09:39:00 -0400 - 9 days ago

Portnoy Law Firm Announces Class Action on Behalf of Immutep Limited Investors

May 7, 2026, 9:03 AM EDT - 9 days ago

IMMUTEP LIMITED (IMMP) INVESTOR ALERT Investors With Large Losses in Immutep Limited Should Contact Bernstein Liebhard LLP To Discuss Their Rights

IMMP

Wed, 06 May 2026 16:26:00 -0400 - 9 days ago

IMMP Stockholder Alert: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Class Action Lawsuit Against Immutep Limited

Wed, 06 May 2026 14:08:00 -0400 - 10 days ago

IMMP DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Immutep (IMMP) Investors of Securities Class Action Deadline on July 6, 2026

Wed, 06 May 2026 12:30:00 -0400 - 10 days ago

ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Immutep Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action - IMMP

Wed, 06 May 2026 12:25:00 -0400 - 10 days ago

Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Immutep Limited American Depository Receipts (IMMP)

Wed, 06 May 2026 12:24:00 -0400 - 10 days ago

Rosen Law Firm Urges Immutep Ltd. (NASDAQ: IMMP) Stockholders to Contact the Firm for Information About Their Rights

Tue, 05 May 2026 17:15:00 -0400 - 10 days ago

Investor Notice: Robbins LLP Informs Investors of the Immutep Limited Class Action

Tue, 05 May 2026 15:41:00 -0400 - 11 days ago

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors It Has Filed a Complaint to Recover Losses Suffered by Purchasers of Immutep Limited American Depositary Receipts and Sets a Lead Plaintiff Deadline of July 6, 2026

Tue, 05 May 2026 14:54:00 -0400 - 11 days ago

Rosen Law Firm Encourages Immutep Ltd. Investors to Inquire About Securities Class Action Investigation - IMMP

Mon, 04 May 2026 20:58:00 -0400 - 11 days ago

IMMP Investor News: If You Have Suffered Losses in Immutep Ltd. (NASDAQ: IMMP), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

Sun, 03 May 2026 21:18:00 -0400 - 12 days ago

ROSEN, A GLOBAL INVESTOR RIGHTS LAW FIRM, Encourages Immutep Ltd. Investors to Inquire About Securities Class Action Investigation - IMMP

Sat, 02 May 2026 20:04:00 -0400 - 13 days ago

ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Immutep Ltd. Investors to Inquire About Securities Class Action Investigation - IMMP

2026-04-30T14:06:28.000Z - 16 days ago

Immutep receives noncompliance notification from Nasdaq

2026-04-16T18:52:15.000Z - 4 weeks ago

3 Penny Stocks to Watch Now, 4/16/26

AGAE BIRD

2026-04-15T13:40:27.000Z - 4 weeks ago

Unusually active option classes on open April 15th

AEO ALLO BULL CHGG EOSE PAAS QUBT

2026-04-15T13:01:30.000Z - 4 weeks ago

Why Is Immutep Stock (IMMP) Up Today?

2026-04-15T12:23:31.000Z - 4 weeks ago

Immutep granted Orphan Drug Designation for eftilagimod alfa

Apr 15, 2026, 8:00 AM EDT - 4 weeks ago

Immutep Receives FDA Orphan Drug Designation for Eftilagimod Alfa in Soft Tissue Sarcoma

2026-03-19T12:28:18.000Z - 2 months ago

Immutep sees progress from Phase I study of LAG-3 agonist for autoimmune disease

Mar 16, 2026, 8:03 AM EDT - 2 months ago

Immutep Limited Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

2026-03-14T00:11:00.000Z - 2 months ago

Why Did Investors Lose Faith In Immutep Stock (IMMP) Today?

2026-03-13T16:52:01.000Z - 2 months ago

Immutep downgraded to Hold from Buy at Maxim

2026-03-13T12:12:46.000Z - 2 months ago

Immutep says IDMC recommends discontinuation for TACTI-004 Phase III study

2026-03-13T09:35:41.000Z - 2 months ago

Immutep downgraded to Neutral from Outperform at Baird

2026-03-13T08:45:13.000Z - 2 months ago

Immutep downgraded to Market Perform from Outperform at Citizens

2026-02-17T09:55:08.000Z - 3 months ago

Immutep initiated with an Outperform at Citizens

2026-02-06T13:06:35.000Z - 3 months ago

Immutep achieves 50% enrollment in global TACTI-004 Phase III trial

Feb 6, 2026, 8:00 AM EST - 3 months ago

Immutep Achieves 50% Enrolment in Global TACTI-004 (KEYNOTE-F91) Phase III Trial in 1L NSCLC

2026-01-29T13:21:20.000Z - 3 months ago

Immutep reports Q2 cash receipts from customers A$4,000

Jan 29, 2026, 8:00 AM EST - 3 months ago

Immutep Quarterly Activities Report Q2 FY26

2025-12-22T13:15:55.000Z - 5 months ago

Immutep announces update on IMP761 from Phase I study

Dec 22, 2025, 8:00 AM EST - 5 months ago

Immutep Announces Positive Update on IMP761, a First-in-Class LAG-3 Agonist Antibody for Autoimmune Diseases, from Phase I Study

2025-12-16T13:15:40.000Z - 5 months ago

Immutep announces progress in global TACTI-004 Phase III, enrollment continues

MRK

Dec 8, 2025, 2:34 AM EST - 5 months ago

India's Dr Reddy's signs licensing pact to sell Immutep's cancer drug

Oct 20, 2025, 8:01 AM EDT - 7 months ago

Primary Endpoint Met in EFTISARC-NEO Phase II Evaluating Neoadjuvant Efti in Soft Tissue Sarcoma and Data Presented at ESMO Congress 2025

Sep 8, 2025, 8:00 AM EDT - 8 months ago

Immutep Announces Data from EFTISARC-NEO Phase II Evaluating Neoadjuvant Efti in Soft Tissue Sarcoma Accepted for Oral Presentation at CTOS 2025

Jul 30, 2025, 8:00 AM EDT - 10 months ago

Immutep Quarterly Activities Report Q4 FY25

Jul 29, 2025, 8:00 AM EDT - 10 months ago

Immutep to Present Pivotal TACTI-004 Trial in Progress Poster at the 2025 World Conference on Lung Cancer

May 27, 2025, 8:00 AM EDT - 1 year ago

Immutep's Efti with Radiotherapy & KEYTRUDA® (pembrolizumab) Meets Primary Endpoint in Phase II for Soft Tissue Sarcoma

Apr 2, 2025, 8:00 AM EDT - 1 year ago

Immutep to Participate in Upcoming Investor Conferences

Jan 31, 2025, 8:00 AM EST - 1 year ago

Immutep Quarterly Activities Report Q2 FY25

Dec 17, 2024, 8:00 AM EST - 1 year ago

Immutep Announces Initial Safety Data from First-in-Human Phase I Trial Evaluating IMP761

Dec 12, 2024, 8:15 AM EST - 1 year ago

Immutep Reports Promising New Data in Head and Neck Cancer at ESMO Immuno-Oncology 2024

Nov 14, 2024, 8:15 AM EST - 1 year ago

Immutep's Efti Shows Excellent Survival Data from INSIGHT-003 Trial in Non-Small Cell Lung Cancer

Oct 29, 2024, 8:00 AM EDT - 1 year ago

Immutep Quarterly Activities Report Q1 FY25

Oct 10, 2024, 8:00 AM EDT - 1 year ago

Immutep to Participate in the 2024 Maxim Healthcare Virtual Summit

Sep 16, 2024, 8:00 AM EDT - 1 year ago

Immutep's Efti in Combination with MSD's KEYTRUDA® Leads to Positive Efficacy with Favourable Safety in First Line Head and Neck Cancer

Jul 31, 2024, 8:00 AM EDT - 1 year ago

Immutep Quarterly Activities Report Q4 FY24

Jul 11, 2024, 6:40 PM EDT - 2 years ago

Immutep Reports Positive Results in First Line Head and Neck Squamous Cell Carcinoma Patients with Negative PD-L1 Expression

Jul 3, 2024, 8:00 AM EDT - 2 years ago

Immutep Announces Details for Oral Presentation at ESMO Virtual Plenary Session and Webcast to Discuss Clinical Results

Jun 25, 2024, 8:00 AM EDT - 2 years ago

Immutep Signs Exclusive License Agreement with Cardiff University for Next Generation Anti-LAG-3 Molecules for Cancer

Jun 5, 2024, 6:00 AM EDT - 2 years ago

Immutep successfully completes institutional placement and institutional component of entitlement offer

Jun 2, 2024, 8:38 PM EDT - 2 years ago

Immutep Announces Clinical Collaboration with MSD to Evaluate Efti in Combination with KEYTRUDA® (pembrolizumab) in Pivotal Phase III Trial

May 15, 2024, 8:00 AM EDT - 2 years ago

Immutep Presents Data from Safety Lead-in Phase of AIPAC-003 at ESMO Breast 2024

May 2, 2024, 8:00 AM EDT - 2 years ago

Positive Initial Clinical Data Reported from Immutep's Efti Combined with Radiotherapy and Checkpoint Inhibitor from Phase II Trial in Soft Tissue Sarcoma

Apr 29, 2024, 8:00 AM EDT - 2 years ago

Immutep Quarterly Activities Report Q3 FY24

Apr 24, 2024, 8:00 AM EDT - 2 years ago

Immutep Announces Positive Preliminary Topline Results from TACTI-003 Cohort B

Apr 18, 2024, 8:00 AM EDT - 2 years ago

Immutep Appoints Leading Research Institute to Conduct First-in-Human Phase I Study of IMP761

Apr 17, 2024, 8:00 AM EDT - 2 years ago

Immutep Receives Positive Feedback from the Spanish Medicines Agency for Upcoming TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer

Mar 5, 2024, 8:00 AM EST - 2 years ago

Immutep Announces First Clinical Data from 90mg Dosing of Efti

Jan 30, 2024, 8:00 AM EST - 2 years ago

Immutep Quarterly Activities Report Q2 FY24

Jan 4, 2024, 8:00 AM EST - 2 years ago

First Patient Dosed in Trial Evaluating Efti and the Anti-PD-L1 Therapy BAVENCIO® in Metastatic Urothelial Cancer

Dec 21, 2023, 8:00 AM EST - 2 years ago

Immutep Receives Constructive Regulatory Feedback on TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer

Dec 7, 2023, 8:00 AM EST - 2 years ago

Immutep Receives A$2.6 million R&D Tax Incentive from French Government

Nov 22, 2023, 8:00 AM EST - 2 years ago

Immutep Announces Site Expansion for INSIGHT-003 Phase I Trial

Nov 9, 2023, 8:00 AM EST - 2 years ago

Immutep Completes Enrollment in TACTI-003 Phase IIb Trial of Efti and KEYTRUDA® in First Line Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma

Nov 6, 2023, 8:00 AM EST - 2 years ago

Immutep Announces Completion of the Safety Lead-In and Opening of the Randomized Phase II of the AIPAC-003 Phase II/III Trial in Metastatic Breast Cancer

Nov 3, 2023, 12:00 PM EDT - 2 years ago

Immutep Announces New Biomarker Data from TACTI-002 Phase II in First Line Non-Small Cell Lung Cancer

Nov 2, 2023, 8:00 AM EDT - 2 years ago

Immutep to Participate in November Investor Events

Oct 31, 2023, 8:00 AM EDT - 2 years ago

Immutep Quarterly Activities Report Q1 FY24

Oct 25, 2023, 8:00 AM EDT - 2 years ago

Immutep receives ~A$1.13 million R&D Tax Incentive